Phio Pharmaceuticals opened higher at $0.85, compared with its previous close of $0.81. In the last trading session, the stock traded between $0.78 and $0.86. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Phio Pharmaceuticals is now worth
$ 0.48
Resulting in a loss of
$ 99.52 (99.52%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.01 (+1.70%)
Day High
$0.86
Day Low
$0.78
Day Open
$0.85
Prev Close
$0.81
Volume
70,620
1W Return
-4.28%
1M Return
-11.08%
3M Return
-23.78%
6M Return
-23.43%
1Y Return
-48.63%
Fundamentals
Market Cap ($ Mn)
10
PE Ratio
-
PB Ratio
1.04
PEG Ratio
-
ROE
-76.33%
ROCE
-80.90%
EPS (TTM)
$-0.36
Investment Returns
1 Week
-4.28%
1 Month
-11.08%
3 Months
-23.78%
6 Months
-23.43%
9 Months
-35.89%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
26Aug
HC Wainwright Reiterates Buy on Phio Pharmaceuticals With $14 Target
HC Wainwright & Co. reiterates a Buy rating on Phio Pharmaceuticals. Analyst Matthew Keller maintains the price target at $14 per share. The firm continues to view the stock as undervalued relative to its target.
2mo ago
11Aug
Phio Pharmaceuticals secures US patent allowance for PH-894
Phio Pharmaceuticals Corp. received a U.S. Notice of Allowance for a patent on PH-894, protecting its chemical structure and genetic sequencing. The IP covers applications for proliferative and infectious diseases, strengthening the company's INTASYL™ platform portfolio. This milestone enhances the defensibility of the BRD4-silencing candidate.
3mo ago
25Jun
Phio Pharma to discuss siRNA oncology at Force Family Office chat
Phio Pharmaceuticals Corp. announced that CEO Robert Bitterman will participate in a fireside chat with Force Family Office to discuss its INTASYL siRNA program. The session will highlight the program's role as a differentiated immuno-oncology strategy. James Cardia, Ph.D., will join to explore siRNA therapy and skin cancer treatments.
4mo ago
24Jun
Phio Pharmaceuticals commences commercial-scale PH-762 production
Phio Pharmaceuticals has begun manufacturing the first commercial-scale batch of PH-762 drug substance at Nitto Denko Avecia, following a June 2025 agreement. This progress supports the intratumoral program's next phase after the completion of a Phase 1b dose-escalation study for cutaneous carcinomas.
